Jazz Pharmaceuticals (JAZZ) - FREE Research Report Falberg Kathryn E who is EVP and CFO at Jazz Pharmaceuticals sold 2,000 shares at $131.82 on Jan. 10, 2014. Following this transaction, the EVP and CFO owned 126,721 shares meaning that the stake was reduced by 1.55% with the 2,000-share transaction. The shares most recently traded at $144.69, up $12.87, or 8.89% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:
4-Week # shares sold: 3,000
12-Week # shares sold: 6,000
24-Week # shares sold: 42,208
The average volume for Jazz Pharmaceuticals has been 725,600 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $7.9 billion and is part of the health care sector and drugs industry. Shares are up 9.48% year-to-date as of the close of trading on Friday. Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. The company has a P/E ratio of 25.3. Currently there are 11 analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold. Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREETheStreet Quant Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.